HER2 Circulating Tumor Cells in Gastric Cancer
The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.
Gastric Cancer
To survey the frequency of HER2(+) CTC in gastric cancer, 24month
We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.